Please wait while the formulary information is being retrieved.
ELELYSO (TALIGLUCERASE ALFA)
- Gaucher's disease
200 unit intravenous solution
- Infuse 60 unit/kg over 60-120 minute(s) by intravenous route every 2 weeks
Gaucher's disease
- Infuse 60 unit/kg over 60-120 minute(s) by intravenous route every 2 weeks
- Infuse 11 unit/kg over 60-120 minute(s) by intravenous route every 2 weeks
- Infuse 73 unit/kg over 60-120 minute(s) by intravenous route every 2 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
ELELYSO (TALIGLUCERASE ALFA)
- Gaucher's disease
- None
- Acute abdominal pain
- Arthralgias
- Back pain
- Dizziness
- Flushing
- Headache disorder
- Hypersensitivity drug reaction
- Limb pain
- Nausea
- Pruritus of skin
- Urticaria
- Vomiting
More Frequent
Severe
Less Severe
- None
- Chest pain
- Diarrhea
- Erythema
- Fatigue
- Skin rash
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Hypotension
Less Severe
- Chest tightness
- Wheezing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Taliglucerase
- Severity Level:
2
- Additional Notes: Insuff human data avail, consider maternal tx benefits vs potential fetal risks
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Taliglucerase
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Gaucher's disease | |
| E75.22 | Gaucher disease |
| 0-9 | A-Z |
|---|---|
| E75.22 | Gaucher disease |
Formulary Reference Tool